Xencor Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Xencor şirketinin kazançları yıllık ortalama -37.8% oranında azalırken, Biotechs sektörünün kazançları yıllık 7.7% oranında artan oldu. Gelirler yıllık ortalama 2.6% oranında artan oldu.

Anahtar bilgiler

-37.8%

Kazanç büyüme oranı

-36.3%

EPS büyüme oranı

Biotechs Sektör Büyümesi	-14.6%
Gelir büyüme oranı	2.6%
Özkaynak getirisi	-28.0%
Net Marj	-232.8%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Xencor nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:XE9 Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	85	-198	60
30 Jun 24	134	-177	58
31 Mar 24	162	-133	52
31 Dec 23	168	-126	52
30 Sep 23	145	-119	49
30 Jun 23	113	-128	49
31 Mar 23	98	-140	49
31 Dec 22	165	-55	46
30 Sep 22	297	30	45
30 Jun 22	289	22	43
31 Mar 22	327	109	41
31 Dec 21	275	83	39
30 Sep 21	163	-4	35
30 Jun 21	179	24	32
31 Mar 21	124	-64	30
31 Dec 20	123	-69	30
30 Sep 20	84	-83	29
30 Jun 20	71	-80	27
31 Mar 20	77	-61	26
31 Dec 19	157	27	24
30 Sep 19	165	36	23
30 Jun 19	172	49	24
31 Mar 19	153	39	23
31 Dec 18	41	-70	22
30 Sep 18	59	-45	21
30 Jun 18	30	-71	18
31 Mar 18	43	-53	17
31 Dec 17	46	-38	17
30 Sep 17	22	-55	16
30 Jun 17	30	-40	15
31 Mar 17	84	15	14
31 Dec 16	109	45	13
30 Sep 16	103	40	12
30 Jun 16	99	38	12
31 Mar 16	34	-18	12
31 Dec 15	28	-18	11
30 Sep 15	12	-27	10
30 Jun 15	9	-23	9
31 Mar 15	9	-19	8
31 Dec 14	10	-16	7
30 Sep 14	6	-19	4
30 Jun 14	8	-17	3
31 Mar 14	11	85	2
31 Dec 13	10	85	3

Kaliteli Kazançlar: XE9 şu anda kârlı değil.

Büyüyen Kar Marjı: XE9 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: XE9 kârlı değildir ve zararlar son 5 yılda yılda 37.8% oranında artmıştır.

Büyüme Hızlandırma: XE9 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: XE9 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -21.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: XE9 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -27.98% ) sahiptir.

Xencor Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: US$0.70 loss per share (vs US$0.40 loss in 3Q 2023)

Second quarter 2024 earnings released: US$1.07 loss per share (vs US$0.37 loss in 2Q 2023)

First quarter 2024 earnings released: US$1.11 loss per share (vs US$1.02 loss in 1Q 2023)

Full year 2023 earnings released: US$2.08 loss per share (vs US$0.93 loss in FY 2022)

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Third quarter 2023 earnings released: US$0.40 loss per share (vs US$0.55 loss in 3Q 2022)

Recent updates

Now 22% overvalued after recent price rise

Third quarter 2024 earnings released: US$0.70 loss per share (vs US$0.40 loss in 3Q 2023)

Xencor, Inc. Doses First Subject in Phase 1/2 Study of XmAb®?942 in Development for Patients with Inflammatory Bowel Disease

Now 22% overvalued after recent price rise

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Now 24% overvalued after recent price rise

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Now 28% undervalued after recent price drop

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.07 loss per share (vs US$0.37 loss in 2Q 2023)

First quarter 2024 earnings released: US$1.11 loss per share (vs US$1.02 loss in 1Q 2023)

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Co-Founder recently sold €270k worth of stock

New minor risk - Profitability

Full year 2023 earnings released: US$2.08 loss per share (vs US$0.93 loss in FY 2022)

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Third quarter 2023 earnings released: US$0.40 loss per share (vs US$0.55 loss in 3Q 2022)

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor Announces Planned Retirement of Senior Vice President John Kuch

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.57 loss in 2Q 2022)

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Insufficient new directors

First quarter 2023 earnings released: US$1.02 loss per share (vs US$0.40 profit in 1Q 2022)

Co-Founder recently sold €172k worth of stock

Full year 2022 earnings released: US$0.93 loss per share (vs US$1.42 profit in FY 2021)

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Senior VP & Chief Medical Officer recently sold €95k worth of stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.69 loss in 3Q 2021)

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.90 profit in 2Q 2021)

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

First quarter 2022 earnings released: EPS: US$0.40 (vs US$0.043 loss in 1Q 2021)

Co-Founder recently sold €65k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Xencor, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.22 loss in 3Q 2020)

Director Yujiro Hata has joined 3rd company board

Second quarter 2021 earnings released: EPS US$0.90 (vs US$0.61 loss in 2Q 2020)

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000E Value Index

Sotrovimab Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

First quarter 2021 earnings released: US$0.043 loss per share (vs US$0.14 loss in 1Q 2020)

Xencor, Inc. Doses First Subject in Phase 1 Study of XMAB®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases

Co-Founder recently sold €106k worth of stock

Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics

Full year 2020 earnings released: US$1.21 loss per share (vs US$0.47 profit in FY 2019)

Revenue beats expectations

Xencor, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €42.20

Xencor, Inc. and The University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer

New 90-day high: €38.20

Senior VP & Chief Medical Officer recently sold €135k worth of stock